吸入舒利迭对重度稳定期慢性阻塞性肺疾病的肺功能临床分析  

Clinical analysis of using salmeterol and fluticason in the treatment of severe COPD in stabilization

作　　者：李世明[1] 

机构地区：[1]四川宜宾市第二人民医院,四川644000

出　　处：《中华肺部疾病杂志（电子版）》2010年第6期25-27,共3页Chinese Journal of Lung Diseases(Electronic Edition)

摘　　要：目的探讨沙美特罗/氟替卡松治疗是否能改善慢性阻塞性肺疾病(chronicobstructive pulmonary disease,COPD)缓解期患者的肺通气功能。方法重度COPD稳定期患者64例随机分为治疗组和对照组。对照组给予常规治疗,应用氨茶碱、异丙托溴铵等。治疗组在常规治疗的基础上吸入沙美特罗/氟替卡松(50/250μg)。在治疗前,治疗后24周测定肺功能,评价肺功能改善状况。结果治疗组在治疗后24周肺功能有明显改善,和对照组相比有显著差异(P<0.05)。结论沙美特罗/氟替卡松是改善稳定期重度COPD患者肺功能的一种有效治疗方法。Objective To observe curative effect of pulmonary function for severe chronic obstructive pulmonary disease （COPD）case in stabilization period when inhaling salmeteml and fluticason. Methods 64 severe COPD cases of stabilization period were randomly divided into two groups. The comparative group was given routine treatment including salbutamol, ipratmpium and aminophylline. In addition to the routine therapy, the treatment group inhaled salmeteml and fluticason（50/250μg）. The pulmonary functions were observed before the treatment, and 24 weeks after the treatment. Results The pulmonary functions of the treatment group improved by the end of 24 weeks. The significant diferences were seen between the treatment group and the comparative group. The treatment group had better curative effect than the comparative group. Conclusion The treatment of severe COPD cases in the stabilization period inhaling salmeterol and fluticason was effective.

关 键 词：重度COPD 沙美特罗/氟替卡松 肺功能 

分 类 号：R563[医药卫生—呼吸系统]